BIOMARIN PHARMACEUTICAL INC
Congressional Trades
Whale Activity
- Increased191
- New72
- Held98
- Decreased171
- Closed65
- No prior filing36
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 20.7M | $1.24B | increased |
| PRIMECAP MANAGEMENT CO/CA/ | 15.0M | $899.3M | increased |
| DODGE & COX | 14.6M | $877.5M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 8.7M | $523.4M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8.4M | $502.3M | decreased |
| STATE STREET CORP | 8.3M | $500.4M | increased |
| FMR LLC | 7.3M | $440.6M | increased |
| VIKING GLOBAL INVESTORS LP | 7.2M | $430.4M | decreased |
| Deep Track Capital, LP | 6.4M | $382.5M | increased |
| Vestal Point Capital, LP | 5.5M | $331.5M | decreased |
| DIMENSIONAL FUND ADVISORS LP | 4.4M | $263.9M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 3.8M | $225.4M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Friberg Gregory REVP, Chief R&D Officer | Sale | −5,147 | $58.81 | $303K | Nov 18, 2026 | Form 4 ↗ |
| Plenge Robert MDirector | Grant / award | +6,140 | $0.00 | $0 | Sep 10, 2026 | Form 4 ↗ |
| Davis George EricEVP, Chief Legal Officer | Sale | −17.6K | $66.28 | $1.2M | Sep 2, 2026 | Form 4 ↗ |
| Countouriotis AthenaDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Walbert Timothy PDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Ho MaykinDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| HOMBACH ROBERT J.Director | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Enyedy Mark JDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Dere Willard HDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| CLARK IAN TDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Bodem Barbara W.Director | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| ANDERSON ELIZABETH MDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Hubbard CristinEVP, Chief Commercial Officer | Tax withholding | −2,318 | $50.20 | $116K | May 20, 2026 | Form 4 ↗ |
| Friberg Gregory REVP, Chief R&D Officer | Sale | −3,281 | $53.85 | $177K | May 7, 2026 | Form 4 ↗ |
| Davis George EricEVP, Chief Legal Officer | Tax withholding | −1,273 | $56.05 | $71K | Mar 18, 2026 | Form 4 ↗ |
| Guyer Charles GregEVP, Chief Technical Officer | Tax withholding | −1,693 | $56.05 | $95K | Mar 17, 2026 | Form 4 ↗ |
| Mueller BrianEVP, Chief Financial Officer | Tax withholding | −2,117 | $56.05 | $119K | Mar 17, 2026 | Form 4 ↗ |
| Hardy AlexanderChief Executive Officer · Director | Tax withholding | −4,252 | $56.05 | $238K | Mar 17, 2026 | Form 4 ↗ |
| Hubbard CristinEVP, Chief Commercial Officer | Tax withholding | −1,245 | $56.05 | $70K | Mar 17, 2026 | Form 4 ↗ |
| Friberg Gregory REVP, Chief R&D Officer | Tax withholding | −1,629 | $56.05 | $91K | Mar 17, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Dodge & Cox Stock Fund Dodge & Cox Funds | 9.8M | $559.0M | 0.47% | Jun 30, 2026 |
| iShares Core S&P Mid-Cap ETF iShares Trust | 6.6M | $378.5M | 0.30% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 6.1M | $351.4M | 0.02% | Jun 30, 2026 |
| VANGUARD CAPITAL OPPORTUNITY FUND VANGUARD HORIZON FUNDS | 5.2M | $295.7M | 0.90% | Jun 30, 2026 |
| VANGUARD PRIMECAP FUND VANGUARD CHESTER FUNDS | 5.0M | $284.4M | 0.30% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 4.4M | $253.7M | 0.13% | Jun 30, 2026 |
| Capital World Growth & Income Fund | 2.6M | $168.0M | 0.11% | Aug 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 2.6M | $146.1M | 0.31% | Jun 30, 2026 |
| Fidelity Contrafund | 2.5M | $144.7M | 0.08% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.2M | $126.8M | 0.13% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list BMRN's shares (CUSIP 09061G101), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Viking Global Opportunities Portfolio GP LLCSCHEDULE 13G · passive (13G) · 1.1M shares0.6%
Nov 20, 2026 · ↗ - Viking Global Opportunities GP LLCSCHEDULE 13G · passive (13G) · 1.1M shares0.6%
Nov 20, 2026 · ↗ - Viking Global Opportunities Parent GP LLCSCHEDULE 13G · passive (13G) · 1.1M shares0.6%
Nov 20, 2026 · ↗ - Viking Long Fund Master Ltd.SCHEDULE 13G · passive (13G) · 2.4M shares1.2%
Nov 20, 2026 · ↗ - Viking Long Fund GP LLCSCHEDULE 13G · passive (13G) · 2.4M shares1.2%
Nov 20, 2026 · ↗ - Viking Global Equities Master Ltd.SCHEDULE 13G · passive (13G) · 5.7M shares2.9%
Nov 20, 2026 · ↗ - Viking Global Equities II LPSCHEDULE 13G · passive (13G) · 116.6K shares0.1%
Nov 20, 2026 · ↗ - VIKING GLOBAL PERFORMANCE LLCSCHEDULE 13G · passive (13G) · 5.8M shares3.0%
Nov 20, 2026 · ↗ - Shabet Rose SharonSCHEDULE 13G · passive (13G) · 9.4M shares4.8%
Nov 20, 2026 · ↗ - HALVORSEN OLE ANDREASSCHEDULE 13G · passive (13G) · 9.4M shares4.8%
Nov 20, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming BIOMARIN PHARMACEUTICAL INC as the client.
Government Contracts
No federal contract awards found for BIOMARIN PHARMACEUTICAL INC.
U.S. Patents
No USPTO patent applications found for BIOMARIN PHARMACEUTICAL INC.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Operating income | $409.5M | $484.2M | $185.8M | $161.0M | -$82.3M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | -$64.1M |
| Diluted EPS | $1.80 | $2.21 | $0.87 | $0.75 | -$0.35 |
| Operating cash flow | $828.0M | $572.8M | $159.3M | $175.9M | $304.5M |
| Cash and equivalents | $1.31B | $942.8M | $755.1M | $724.5M | $587.3M |
| Total assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B |
| Total liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B |
| Shareholders' equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B |
As BIOMARIN PHARMACEUTICAL INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
No stock splits in BMRN's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 2, 2026
EDGAR ↗ - 8-K · Items 2.02Results of operationsOct 6, 2026
EDGAR ↗ - 8-K · Items 1.01Material agreementSep 30, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 15, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeSep 14, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 1, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureAug 31, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureAug 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K/A · Items 8.01, 9.01Other eventsJul 13, 2026
EDGAR ↗









